Understanding how B cells contribute to liver disease linked to obesity
Mechanisms of B Cell Pathogenicity in Non-Alcoholic Fatty Liver Disease
This study is looking at how a type of immune cell called B lymphocytes might affect liver health in people with non-alcoholic fatty liver disease (NAFLD), especially as it relates to obesity and gut bacteria, to find new ways to improve treatments for this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10624263 on NIH RePORTER |
What this research studies
This research investigates the role of B lymphocytes, a type of immune cell, in the development and progression of non-alcoholic fatty liver disease (NAFLD), which is increasingly common due to obesity. The study focuses on how these B cells may contribute to liver inflammation and damage, particularly in the context of changes in gut bacteria. By examining the interactions between B cells and other immune components in the liver, the research aims to uncover new mechanisms that could lead to better treatments for NAFLD. Patients may be involved in providing samples or data to help understand these processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-alcoholic fatty liver disease, particularly those with obesity-related complications.
Not a fit: Patients without non-alcoholic fatty liver disease or those with liver conditions unrelated to obesity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating non-alcoholic fatty liver disease and its complications.
How similar studies have performed: Previous research has shown that targeting immune cells can be effective in treating autoimmune and inflammatory diseases, suggesting potential for success in this area as well.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Revelo, Xavier — University of Minnesota
- Study coordinator: Revelo, Xavier
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.